{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:11:21Z","timestamp":1778134281866,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.ejps.2012.04.003","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T14:18:06Z","timestamp":1334845086000},"page":"244-255","source":"Crossref","is-referenced-by-count":48,"title":["Prediction of the in vivo OATP1B1-mediated drug\u2013drug interaction potential of an investigational drug against a range of statins"],"prefix":"10.1016","volume":"47","author":[{"given":"Pradeep","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline J.","family":"Butters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Elsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Surry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2012.04.003_b0005","doi-asserted-by":"crossref","first-page":"17159","DOI":"10.1074\/jbc.274.24.17159","article-title":"Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1","volume":"274","author":"Abe","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2012.04.003_b0245","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.109.028654","article-title":"Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs","volume":"37","author":"Ahlin","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2012.04.003_b0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","article-title":"Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites","volume":"78","author":"Backman","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl.","key":"10.1016\/j.ejps.2012.04.003_b0020","first-page":"951","article-title":"Rifamycin SV: a review","volume":"15","author":"Bergamini","year":"1965","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2012.04.003_b0025","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0091270009357432","article-title":"Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers","volume":"50","author":"Bergman","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2012.04.003_b0030","unstructured":"Business Insights Report: Jan 2007. The Cardiovascular Market Outlook to 2011, Business Insights, IMS Health."},{"key":"10.1016\/j.ejps.2012.04.003_b0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/dmd.104.002477","article-title":"Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1","volume":"33","author":"Chen","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2012.04.003_b0040","series-title":"Therapeuic Drugs","author":"Dollery","year":"1999"},{"key":"10.1016\/j.ejps.2012.04.003_b0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2012.04.003_b0050","series-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Hardman","year":"2001"},{"key":"10.1016\/j.ejps.2012.04.003_b0055","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s11095-007-9446-6","article-title":"Multiple inhibition mechanisms and prediction of drug\u2013drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil\u2013drug interactions","volume":"25","author":"Hinton","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2012.04.003_b0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans","volume":"311","author":"Hirano","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0065","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug\u2013drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2012.04.003_b0070","doi-asserted-by":"crossref","first-page":"37161","DOI":"10.1074\/jbc.274.52.37161","article-title":"A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters","volume":"274","author":"Hsiang","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2012.04.003_b0075","unstructured":"Huang, S.M., 2006. Draft Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis, and Implications for Dosing and Labeling. US Food and Drug Administration. Available at: <http:\/\/www.accessdata.fda.gov\/scripts\/oc\/ohrms\/dailylist.cfm?yr=2006&mn=9&dy=12> (accessed on 12.04.10)."},{"key":"10.1016\/j.ejps.2012.04.003_b0080","unstructured":"Huang, S.M., Ellis, A.L., Grimm, S., Wang, Y., 2004. AAPS Annual Meeting Abstracts. Assessed at: <http:\/\/www.aapsj.org\/abstracts\/AM_2004\/AAPS2004-002183.PDF>."},{"key":"10.1016\/j.ejps.2012.04.003_b0085","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2003.02041.x","article-title":"Database analyses for the prediction of in vivo drug\u2013drug interactions from in vitro data","volume":"57","author":"Ito","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2012.04.003_b0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug\u2013drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2012.04.003_b0095","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","article-title":"Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"81","author":"Lau","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1\u22175, SLCO1B1\u221715 and SLCO1B1\u221715+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejps.2012.04.003_b0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-011-0564-9","article-title":"In Vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug\u2013drug interactions","volume":"29","author":"Karlgren","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2012.04.003_b0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0378-5173(90)90389-L","article-title":"Rate and equilibrium constants for acid-catalyzed lactone hydrolysis of HMG-CoA reductase inhibitors","volume":"66","author":"Kaufman","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2012.04.003_b0255","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1023\/A:1018923325359","article-title":"The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981","volume":"10","author":"Kearney","year":"1993","journal-title":"Pharm Res."},{"key":"10.1016\/j.ejps.2012.04.003_b0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2012.04.003_b0115","doi-asserted-by":"crossref","first-page":"G156","DOI":"10.1152\/ajpgi.2000.278.1.G156","article-title":"A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane","volume":"278","author":"Konig","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejps.2012.04.003_b0120","series-title":"The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs","author":"Kucers","year":"1997"},{"key":"10.1016\/j.ejps.2012.04.003_b0125","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0260","doi-asserted-by":"crossref","first-page":"P33","DOI":"10.1016\/j.clpt.2003.11.125","article-title":"An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers","volume":"75","author":"Mathew","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/jpet.108.148411","article-title":"The 8th and 9th transmembrane domains in organic anion transporting polypeptide (OATP) 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17\u03b2-d-glucuronide","volume":"329","author":"Miyagawa","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0265","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/00498250601188808","article-title":"Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans","volume":"37","author":"Nakagomi-Hagihara","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2012.04.003_b0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/00498250701278442","article-title":"Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1","volume":"37","author":"Nakagomi-Hagihara","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2012.04.003_b0140","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3565(24)29609-9","article-title":"Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes","volume":"297","author":"Nakai","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2012.04.003_b0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2012.04.003_b0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0160","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/dmd.106.012930","article-title":"Substrate-dependent drug\u2013drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3","volume":"35","author":"Noe","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2012.04.003_b0165","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejps.2012.04.003_b0170","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejps.2012.04.003_b0175","unstructured":"Pharmacpedium\u2122, NDA Application number NDA22-291."},{"key":"10.1016\/j.ejps.2012.04.003_b0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/00498250903351013","article-title":"Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug\u2013drug interaction to support regulatory submissions","volume":"40","author":"Sharma","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2012.04.003_b0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0210","doi-asserted-by":"crossref","first-page":"80A","DOI":"10.1016\/S0002-9149(05)80024-4","article-title":"Pharmacokinetics of the combination of fluvastatin and gemfibrozil","volume":"76","author":"Spence","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejps.2012.04.003_b0215","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/17460440802642484","article-title":"Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist","volume":"4","author":"Stasi","year":"2009","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejps.2012.04.003_b0220","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2165\/00003495-198836030-00004","article-title":"Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia","volume":"36","author":"Todd","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2012.04.003_b0225","unstructured":"Ulvestad, M. (2007). Comparison of three in vitro models expressing the membrane drug transporter OATP1B1. Master\u2019s Thesis at Faculty of Mathematics and Natural Sciences, University of Oslo."},{"key":"10.1016\/j.ejps.2012.04.003_b0270","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2012.04.003_b0275","first-page":"1359","article-title":"Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9","volume":"29","author":"Wen","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2012.04.003_b0230","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1021\/jm9810102","article-title":"Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach","volume":"41","author":"Winiwarter","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2012.04.003_b0235","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1124\/dmd.111.040477","article-title":"Kinetic characterization of rat hepatic uptake of 16 actively transported drugs","volume":"39","author":"Yabe","year":"2011","journal-title":"Drug Metab. Dispos."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098712001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098712001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:20:05Z","timestamp":1742955605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098712001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0928098712001728"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2012.04.003","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}